EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of fibrin(ogen) degradation products on blood viscosity values during thrombolysis



Effect of fibrin(ogen) degradation products on blood viscosity values during thrombolysis



Clinical Hemorheology 13(1): 13-22



This study concerns the effect of intravenous thrombolysis in patients suffering from Peripheral Obliterative Arterial Disease (POAD) at the stage of "Accelerated Limb Ischemia" (ALI). In a previous study on 17 patients, where Streptokinase was employed, there was complete or partial reopening of obstructed vessels in 5 cases and an improvement of clinical conditions in 10 cases. Unfortunately, 6 (35%) patients experienced significant side effects.

(PDF 0-2 workdays service: $29.90)

Accession: 008531851

Download citation: RISBibTeXText



Related references

Complementary effects of plasmin and fibrin ogen degradation products on platelet function during thrombolysis. Clinical Research 40(2): 376A, 1992

Effect of internal hemorrhage on fibrin(ogen) degradation products in canine blood. American Journal of Veterinary Research 47(7): 1620-1621, 1986

Catheter-directed intra-arterial thrombolysis: size of soluble fibrin(ogen) degradation products studied by electrophoresis and immunoblotting. Blood Coagulation & Fibrinolysis 10(4): 189-195, 1999

Peptide 6a a fibrin ogen degradation products increases coronary blood flow. American Journal of Physiology 249(3 PART 2): H457-H462, 1985

Use of monoclonal antibodies to fibrinogen, fibrin and fibrin (ogen) degradation products in atherosclerosis. NATO ASI series Series A Life sciences19(219): 189-197, 1991

The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression. Contemporary Oncology 17(2): 113-119, 2013

Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis 9(1): 109-121, 1989

The effect of fibrinogen degradation products and some lysine analogues on the dissociation of plasmin(ogen)-fibrin complexes. Thrombosis Research 16(5-6): 705-713, 1979

Content of soluble fibrin monomeric complexes, factor XIII and fibrin(ogen) degradation products in neonatal asphyxia. Archives of Gynecology 228(1-4): 626-627, 1979

Effect of fibrinogen, fibrin and fibrin (ogen) degradation products on the tissue plasminogen activator and plasminogen activator inhibitor-1 expressions of vascular endothelial cells in coculture system. Zhonghua Xin Xue Guan Bing Za Zhi 36(1): 62-67, 2009

Effect of fibrinogen, fibrin and fibrin ogen degradation products on the tissue plasminogen activator and plasminogen activator inhibitor-1 expressions of vascular endothelial cells in coculture system. Zhonghua Xinxueguanbing Zazhi 36(1): 62-67, 2008

Ca binding of rat fibrinogen and fibrin(ogen) degradation products. Febs Letters 93(1): 177-180, 1978

The fibrin(ogen) degradation products and platelets in meningococcal infection. Quaderni Sclavo di Diagnostica Clinica E di Laboratorio 9(4): 887-892, 1973

Catabolism of purified rat fibrin(ogen) plasmin degradation products in rats. Thrombosis and Haemostasis 48(1): 59-61, 1982

Calcium-binding properties of human fibrin(ogen) and degradation products. Febs Letters 98(2): 257-259, 1979